525 Cartier Boulevard West
Tel: 450-965-8213 ext: 100
About BiodextrisBiodextris is comprised of experienced product development scientist located in Laval (Montreal), Quebec. The group has worked together since 2002, as part of ID Biomedical and later GSK-Vaccines. We have developed numerous products for all phases of clinical development for programs conducted in the US, Canada and Europe.
Our history leaves us with the know-how for high quality, robust, commercial product development combined with flexibility and the sense of urgency inherent in smaller organizations.
We look forward to sharing this expertise with you.
CEO & President: Joseph Zimmermann
Director, Analytical Services: Christine Jacques
Director, Process Services: Paul Rice
Please click here for Biodextris' services.
2 articles with Biodextris
Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has entered into a material transfer agreement with Biodextris Inc. for the use of three intranasal mucosal adjuvants in the Company’s Terra CoV-2 vaccine against COVID-19. Adjuvants are added to vaccines to enhance their immunogenicity. BDX100, BDX300 and BDX301 are proteosome-based adjuvants comprised of proteins and lipopolysaccharides
Accinov And BiodextrisTeam Up To Provide A Unique Contract Development And Manufacturing Service Package